课题基金 / 基金详情

Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis

Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis
siRNA纳米复合物与PD-L1抑制剂联合治疗酒精性肝纤维化
批准号:
10451030
负责人:
Kun Cheng
金额:
$4.67万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-15 至 2023-06-30

项目摘要

项目成果

Kun Cheng的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 此行政补充申请的目的是购买SpectraMax iD 5多功能 模式酶标仪底部发光读取模式。SpectraMax iD 5多模式 酶标仪是一款五模式酶标仪,可测量吸光度、荧光、发光、时间和温度。 分辨荧光(TRF)和可调荧光偏振(FP),用于广泛的 应用.我们目前有一个15岁的读板器(SpectraMax Gemini XPS),它不是 正常工作.此外,我们的酶标仪是旧型号,不能用于蛋白结合 使用HTRF进行测定。 我们已完成母补助金目的1的全部工作,以及目的2的大部分工作。为 在目标2和3的其余研究中,我们将严重依赖于多模式酶标仪的使用, 经常进行蛋白结合分析、细胞摄取研究、免疫测定、细胞活力分析, ELISA、BCA测定、ALT/AST测定、蛋白质印迹和细胞增殖测定。因此,有一个 我们急需购买新的SpectraMax iD 5酶标仪用于我们的研究。 多模式酶标仪的收购将大大提高我们的能力, 在研究上取得了很好的进展。这对于拟议的动物研究的成功至关重要, 评价PCBP 2 siRNA纳米复合物与以下物质组合的稳定性、生物分布和活性: 抗PD-L1抑制剂在大鼠肝纤维化模型中的作用。
英文摘要
Project Summary The purpose of this administrative supplement application is to purchase a SpectraMax iD5 Multi- Mode Microplate Reader with bottom luminescence read mode. The SpectraMax iD5 Multi-Mode Microplate Reader is a five-mode reader that measures absorbance, fluorescence, luminescence, time- resolved fluorescence (TRF), and tunable fluorescence polarization (FP) for a broad range of applications. We currently have a 15-year-old plate reader (SpectraMax Gemini XPS), which is not working properly. In addition, our plate reader is an old model, which cannot be used for protein binding assay using HTRF. We have completed all the work in Aim 1 and most of the work in Aim 2 of the parent grant. For the rest studies in Aims 2 and 3, we will heavily depend on the use of a multi-mode microplate reader to frequently conduct protein binding assay, cellular uptake study, immunoassay, cell viability assay, ELISA, BCA assay, ALT/AST assay, western blot, and cell proliferation assay. Therefore, there is an urgent need to purchase the new SpectraMax iD5 plate reader for our research. The acquisition of the Multi-Mode Microplate Reader will significantly enhance our capability to make good progress in the research. This is essential for the success of the proposed animal studies to evaluate the stability, biodistribution, and activity of the PCBP2 siRNA nanocomplex in combination with the anti-PD-L1 inhibitor in a rat model of liver fibrosis.
期刊论文(29)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1021/acs.jmedchem.2c00539
发表时间: 2022-09-22
期刊: JOURNAL OF MEDICINAL CHEMISTRY
影响因子: 7.3
作者: [Cheng, Kun, Fetse, John, Zhao, Zhen, Liu, Hao, Mamani, Umar-Farouk, Mustafa, Bahaa, Adhikary, Pratik, Ibrahim, Mohammed, Liu, Yanli, Patel, Pratikkumar, Nakhjiri, Maryam, Alahmari, Mohammed, Li, Guangfu]
通讯作者: Li, Guangfu
DOI: 10.1021/mp500426r
发表时间: 2014-10-06
期刊: Molecular pharmaceutics
影响因子: 4.9
作者: [Shukla RS, Qin B, Cheng K]
通讯作者: Cheng K
DOI: 10.1021/acs.molpharmaceut.6b00933
发表时间: 2017-05-01
期刊: Molecular pharmaceutics
影响因子: 4.9
作者: [Jain A, Barve A, Zhao Z, Jin W, Cheng K]
通讯作者: Cheng K
DOI: 10.1021/acs.molpharmaceut.5b00177
发表时间: 2015-06-01
期刊: Molecular pharmaceutics
影响因子: 4.9
作者: [Chen Z, Jin W, Liu H, Zhao Z, Cheng K]
通讯作者: Cheng K
共 21 条
    Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy
    Development of a targeted delivery platform for checkpoint inhibitors
    Development of a targeted delivery platform for checkpoint inhibitors
    Development of a targeted delivery platform for checkpoint inhibitors
    海外基金